Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
株式のランク #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
株価
$9.60
最終同期: 2025-05-21
時価総額
$1.08B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 OptiNose, Inc. (OPTN)

カテゴリー

OptiNose, Inc.(OPTN)のP/B比率
August 2026 時点のP/B比率 TTM: -2.42
OptiNose, Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は -2.42 です。2023 年末時点でのP/B比率は -25.04 でした。
OptiNose, Inc. の P/B 比率の履歴(2015 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) -2.42 43.80%
2024 -1.68 -93.29%
2023 -25.04 792.27%
2022 -2.81 -95.58%
2021 -63.45 -114.37%
2020 441.64 369.60%
2019 94.05 201.63%
2018 31.18 -49.24%
2017 61.42 -130.42%
2016 -201.90 -28.02%
2015 -280.48 0.00%